Bambuterol
drugOn this page
Also known as SID56463628Barnbuterol
Summary
Bambuterol (CHEMBL521589) is a phase-3 clinical-stage small-molecule β-adrenergic agonist (ATC R03CC12) targeting BCHE; indicated across 2 conditions including obstructive lung disease and pulmonary arterial hypertension.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- ATC class: R03CC12
- Targets: 1 (BCHE)
- Indications: 2 conditions
- Clinical trials: 2
- Chemistry: 367.4 Da · C18H29N3O5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL521589 |
| Name | Bambuterol |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 54766 |
| ChEBI | CHEBI:553827 |
| ATC | R03CC12 |
| Molecular formula | C18H29N3O5 |
| Molecular weight | 367.4 |
| InChIKey | ANZXOIAKUNOVQU-UHFFFAOYSA-N |
SMILES: CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O
IUPAC name: [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate
ChEBI definition: A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.
Pharmacological roles (ChEBI): β-adrenergic agonist, prodrug, bronchodilator agent, anti-asthmatic drug, EC 3.1.1.7 (acetylcholinesterase) inhibitor, sympathomimetic agent, tocolytic agent.
Also known as: Bambuterol, SID56463628, BAMBUTEROL, bambuterol, Barnbuterol
Parent form; salt/anhydrous children: CHEMBL1603534
Patent coverage: 2,430 distinct patent families (9,996 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| BCHE | butyrylcholinesterase | Inhibition | 8.5 | 0.1% | P06276 |
Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Cholinesterase, Beta-lactamase, Beta-2 adrenergic receptor, Acetylcholinesterase, Voltage-gated inwardly rectifying potassium channel KCNH2, Cytochrome P450 2D6, Acetylcholinesterase, Cholinesterase.
Bioactivity
ChEMBL activities: 8 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| BCHE | 8.52 | IC50 | 3 | nM | CHEMBL_ACT_18031308 |
| BCHE | 8.52 | IC50 | 3 | nM | CHEMBL_ACT_18117619 |
| BCHE | 8.52 | IC50 | 3 | nM | CHEMBL_ACT_24801597 |
| BCHE | 8.37 | IC50 | 4.29 | nM | CHEMBL_ACT_18031274 |
| P81908 | 6.92 | IC50 | 119.3 | nM | CHEMBL_ACT_18031260 |
| CYP2D6 | 5.7 | IC50 | 2000 | nM | CHEMBL_ACT_7606451 |
| P00811 | 5.3 | Potency | 5012 | nM | CHEMBL_ACT_4750859 |
| ADRB2 | 5.01 | AC50 | 9700 | nM | CHEMBL_ACT_25122633 |
Target pathways
Aggregated over 1 target gene(s): BCHE.
Top Reactome pathways
4 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Neurotransmitter clearance | 1 | BCHE |
| Synthesis of PC | 1 | BCHE |
| Synthesis, secretion, and deacylation of Ghrelin | 1 | BCHE |
| Aspirin ADME | 1 | BCHE |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| acetylcholine catabolic process | 1 |
| xenobiotic metabolic process | 1 |
| learning | 1 |
| negative regulation of cell population proliferation | 1 |
| neuroblast differentiation | 1 |
| peptide hormone processing | 1 |
| choline metabolic process | 1 |
| response to alkaloid | 1 |
| cocaine catabolic process | 1 |
| negative regulation of synaptic transmission | 1 |
| response to glucocorticoid | 1 |
| response to folic acid | 1 |
| response to nutrient | 1 |
| response to xenobiotic stimulus | 1 |
| obsolete cocaine metabolic process | 1 |
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| obstructive lung disease | 3 | MONDO:0002267 | HP:0006536 |
| pulmonary arterial hypertension | 1 | MONDO:0015924 | EFO:0001361 |
Clinical trials
Total trials: 2.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01796730 | PHASE4 | COMPLETED | Effects and Safety of Different Dose of Bambuterol on Chinese COPD Patients |
| NCT01566565 | PHASE1 | COMPLETED | The Safety Evaluation of Drug Combinations Against High Altitude Pulmonary Hypertension |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
29 molecules share ≥1 primary target. Top 29 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| BERBERINE | ChEMBL | Phase 4 (approved) | BCHE |
| DONEPEZIL | ChEMBL | Phase 4 (approved) | BCHE |
| ETHOPROPAZINE | ChEMBL | Phase 4 (approved) | BCHE |
| GALANTAMINE | ChEMBL | Phase 4 (approved) | BCHE |
| NEOSTIGMINE | ChEMBL | Phase 4 (approved) | BCHE |
| NEOSTIGMINE METHYLSULFATE | ChEMBL | Phase 4 (approved) | BCHE |
| PHYSOSTIGMINE | ChEMBL | Phase 4 (approved) | BCHE |
| PHYSOSTIGMINE SALICYLATE | ChEMBL | Phase 4 (approved) | BCHE |
| PYRIDOSTIGMINE | ChEMBL | Phase 4 (approved) | BCHE |
| PYRIDOSTIGMINE BROMIDE | ChEMBL | Phase 4 (approved) | BCHE |
| QUINIDINE | ChEMBL | Phase 4 (approved) | BCHE |
| RASAGILINE | ChEMBL | Phase 4 (approved) | BCHE |
| RESERPINE | ChEMBL | Phase 4 (approved) | BCHE |
| RIVASTIGMINE | ChEMBL | Phase 4 (approved) | BCHE |
| TACRINE | ChEMBL | Phase 4 (approved) | BCHE |
| EBSELEN | ChEMBL | Phase 3 | BCHE |
| LATREPIRDINE | ChEMBL | Phase 3 | BCHE |
| QUERCETIN | ChEMBL | Phase 3 | BCHE |
| SACCHARIN | ChEMBL | Phase 3 | BCHE |
| DIZOCILPINE | ChEMBL | Phase 2 | BCHE |
| EPTASTIGMINE | ChEMBL | Phase 2 | BCHE |
| ESERIDINE | ChEMBL | Phase 2 | BCHE |
| FISETIN | ChEMBL | Phase 2 | BCHE |
| GANSTIGMINE | ChEMBL | Phase 2 | BCHE |
| HUPERZINE A | ChEMBL | Phase 2 | BCHE |
| ICOPEZIL | ChEMBL | Phase 2 | BCHE |
| NEOSTIGMINE BROMIDE | ChEMBL | Phase 2 | BCHE |
| PHENOTHIAZINE | ChEMBL | Phase 2 | BCHE |
| SANGUINARIUM | ChEMBL | Phase 2 | BCHE |
Related Atlas pages
- Genes: BCHE
- Diseases: obstructive lung disease
- Drugs: Berberine, Donepezil, Ethopropazine, Galantamine, Neostigmine, Physostigmine, Pyridostigmine, Quinidine, Rasagiline, Reserpine, Rivastigmine, Tacrine, Ebselen, Latrepirdine, Quercetin, Saccharin